Cleanascite™ Cited In US Patent 20130011413 Titled Method and Pharmaceutical Composition for Treatment of Intestinal Disease

MONMOUTH JUNCTION, NJ.– Inventors Iwakura Yoichiro, Kakuta Shigeru and Suzuki, Shunsuke and assignee The University of Tokyo published United States Patent Application 20130011413 titled, Method and Pharmaceutical Composition for Treatment of Intestinal Disease. The patient details a method for using interleukin-related substances like an IL-17F inhibitor typified by an anti-IL-17F antibody to treat intestinal disease such as colon polyps or colorectal cancer. The patent cites Cleanascite™ from Biotech Support Group in a method for the selection of neutralizing antibodies to mouse IL-17F and IL-17A.

Neutralizing antibodies anti-IL-17F antibody and anti-IL-17A antibodies selected were cultured in serum-free medium and from the supernatant purified antibody was developed. The hybridoma culture supernatant was recovered periodically and a one fourth quantity of Cleanascite (registered trademark) (Biotech Support Group, LLC) was added to the recovered culture supernatant. Next at room temperature the samples were shaked for 10 minutes followed by  centrifugation at 2000rpm to recover the supernatant. Subsequently, filtering, purification, elution, dialysis, filter sterilizing was followed on the samples and protein concentration and the degree of purification was confirmed.   

For detailed protocols of the published article click

Characteristics Of Cleanascite™ Lipid Removal Reagent and Clarification

  • A high binding capacity for lipids with minimal cross-reactivity with proteins
  • Effectively replaces chlorinated/fluorinated hydrocarbons (eg. freon) and it is environmentally friendly.
  • Helps purify antibodies, recombinant proteins, nucleic acids, proteoglycans
  • Ideal for clarifying ascites, serum, cell & tissue culture, bile and organ homogenates
  • Clarifies saliva and fecal components
  • Very low protein binding
  • Does not bind to DNA, RNA, enzymes and proteins
  • Leaves glycoproteins, antibodies, nucleic acids, hemoglobin, proteoglycans, nucleic acids, serum components(such as hormones, nutrients, globulins, clotting factors, transport proteins) alone
  • Extends the life of membrane and chromatographic columns.
  • Enrichment of delipidated tissue samples
  • Ideal for delipidation treatments for downstream processing of large-scale therapeutic proteins, enzymes and monclonal antibodies.

Cleanascite selectively removes lipids, cell debris, lipoproteins, floating fats, impurities from cohn paste, transgenic milk, egg yolk and biological samples for pretreatment of samples prior to purification. The reagent is a solid-phase, non-ionic adsorbent supplied as a suspension in saline, ready for use. Simply add, centrifuge and/or filter. The clarified supernatant is ready for subsequent downstream processing or analysis.

For more information, visit:
Cleanascite™ Lipid Removal Reagent and Clarification

About Biotech Support Group LLC

Biotech Support Group LLC is a leading provider of genomics and proteomics sample preparation products and enrichment reagent kits as well as integrated biotechnology services for life sciences research, biomarker and drug discovery. Based in New Jersey, it’s principal products include: AlbuVoid™ for albumin depletion, Cleanascite™ for lipid adsorption and clarification, NuGel™ for passivated silica-based affinity chromatography, and ProCipitate™ & ProPrep™ for nucleic acid isolation. Currently, Biotech Support Group LLC and ProFACT Proteomics Inc., are collaborating on the development of a proteomics platform used in functional profiling for proteomic analysis and a separations method for generating sub-proteomes used in biomarker and functional proteomic prospecting. For more information, go to: 

Dr.Swapan Roy
Biotech Support Group
1 Deer Park Drive, Suite M, 
Monmouth Junction, NJ 08852, USA 

Cleanascite™ References

Wang W, Ai KX, Yuan Z, Huang XY, Zhang HZ.Different Expression of S100A8 in Malignant and Benign Gallbladder Diseases.Digestive diseases and sciences. 2012.
Hauser-Davis RA, Lima AA, Ziolli RL, Campos RC.First-time report of metalloproteinases in fish bile and their potential as bioindicators regarding environmental contamination. Aquatic Toxicology.2012;110-111:99-106
Farina A, Dumonceau JM, Frossard JL. Proteomic Analysis of Human Bile from Malignant Biliary Stenosis Induced by Pancreatic Cancer Journal of Proteome Research.2009; 8(1):159-69
Guerrier L, Claverol S, Finzi L et al. Contribution of solid-phase hexapeptide ligand libraries to the repertoire of human bile proteins. Journal of Chromatography.2007;1176(1-2):192-205
Chen Bo, Zheng Jian-wei, Wang Jian-ming, et al. Establishment and preliminary analysis of a 2-D human biliary map Chinese Journal of Hepatobiliary Surgery.2007
Chen B, Dong JQ, Chen YJ et al Two-dimensional electrophoresis for comparative proteomic analysis of human bile. Hepatobiliary & pancreatic diseases international.2007 Aug;6(4):402-6
Guerrier L, Claverol S, Finzi L et al Contribution of solid-phase hexapeptide ligand libraries to the repertoire of human bile proteins.Journal of Chromatography A.2007;1176(1-2):192-205
Kristiansen TZ, Bunkenborg J, Gronborg M et al A Proteomic Analysis of Human Bile Molecular and Cellular Proteomics.2004;3:715-728

Biological Matrices

Graeme T Clark, Paul J Russell, and Steven Westwood. Modification without impact: a case study in clinical assay failure due to lipemia. Bioanalysis; 2012: 4,(12):1421-1428

Organ Homogenates

Myerson, J., He, L., Lanza, G., Tollefsen, D. and Wickline, S. Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis. Journal of Thrombosis and Haemostasis.2011;9:1292-1300
Thakuria D, Schmidt O, Liliensiek AK. Field preservation and DNA extraction methods for intestinal microbial diversity analysis in earthwormsJournal of Microbiological Methods.2009;76(3):226-33
Cheng AM, Moore EE, Masuno T et al Normal Mesenteric Lymph Blunts the Pulmonary Inflammatory Response to Endotoxin. Journal of Surgical Research.2006;136(S2):166-171
McNally T, Mackie IJ, Machin SJ et al. Increased levels of beta 2 glycoprotein I antigen and beta 2 glycoprotein I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome British journal of rheumatology.1995 Nov;34(11):1031-6

Red Blood Cells

Antunes RF; Brandao C; Maia M; Arosa FA. Red blood cells release factors with growth and survival bioactivities for normal and leukemic T cells. Immunology and Cell Biology.2011;89(1):111-21

Tracheal Swab Samples

Li D, Wang J, Wang R, Li Y. A nanobeads amplified QCM immunosensor for the detection of avian influenza virus H5N1, Biosensors and Bioelectronics.2011;26(S10):4146-4154
Fu LM, Shinnick TM. Genome-wide exploration of the drug action of capreomycin on Mycobacterium tuberculosis using Affymetrix oligonucleotide GeneChips Journal of Infection.2007;54(S3):277-284
Fu LM, Shinnick TM. Genome-wide analysis of intergenic regions of mycobacterium tuberculosis H37Rv using affymetrix genechips. EURASIP journal on bioinformatics & systems biology.2007:23054

Tissue and Cell Culture

Alhamdani MS, Schroder C, Hoheisel JD. Analysis conditions for proteomic profiling of mammalian tissue and cell extracts with antibody microarrays. Proteomics.2010;10(17):3203-7
Czambel RK, Kharlamov A, Jones SC. Variations of brain endothelial nitric oxide synthase concentration in rat and mouse cortex.Nitric Oxide.2010;22(S1): 51-57


Lijowski M, Caruthers S, Hu G. High-Resolution SPECT-CT/MR Molecular Imaging of Angiogenesis in the Vx2 Model Investigative Radiology.2009;44(1): 15–22
Turner JD, Langley RS, Johnston KL. Wolbachia Lipoprotein Stimulates Innate and Adaptive Immunity through Toll-like Receptors 2 and 6 to Induce Disease Manifestations of Filariasis The Journal of Biological Chemistry.2009;284:22364-22378
Torrelles JB, DesJardin LE, MacNeil J. et al Inactivation of Mycobacterium tuberculosis mannosyltransferase pimB reduces the cell wall lipoarabinomannan and lipomannan content and increases the rate of bacterial-induced human macrophage cell death Glycobiology.2009;19(7):743-755
Cho N, Chueh PJ, Kim C et al Monoclonal antibody to a cancer-specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients. Cancer Immunology, Immunotherapy. 2002;51(3):121-9
Shapiro S, Beenhouwer DO, Feldmesser M et al. Immunoglobulin G Monoclonal Antibodies to Cryptococcus neoformans Protect Mice Deficient in Complement Component C3 Infect. Infection and immunity.2002;70(5):2598-604
Castro AR, Morrill We, Pope V. Lipid Removal from Human Serum Samples Clinical and diagnostic laboratory immunology.2000;7(2):197-199
Nussbaum G, Cleare W, Casadevall A et al Epitope Location in the Cryptococcus neoformans Capsule Is a Determinant of Antibody Efficacy The Journal of experimental medicine.1997;185:685-694


Lucy E. DesJardin Isolation of M. tuberculosis RNA from Sputum Methods in Molecular Medicine.2001;48:133-139
Beenhouwer DO, Shapiro S, Feldmesser M et al. Both Th1 and Th2 Cytokines Affect the Ability of Monoclonal Antibodies To Protect Mice against Cryptococcus neoformans Infection and immunity.2001;69: 6445-6455
Desjardin LE, Perkins MD, Wolski K et al. Measurement of Sputum Mycobacterium tuberculosis Messenger RNA as a Surrogate for Response to Chemotherapy American journal of respiratory and critical care medicine.1999;160(1):203-10
Template Preparation Production Sequencing Protocols. Stanford Genome Technology Center


Iwakura Yoichiro, Kakuta Shigeru, Suzuki, Shunsuke - United States Patent Application 20130011413. Method and Pharmaceutical Composition for Treatment of Intestinal Disease
J Krupey - United States Patent: 5885921 Hydrophobic silica adsorbents for lipids
David C. Jones. United States Patent: 7999084. Devices and methods for reducing matrix effects
DJ Morre, NM McCarty, D Morre et al United States Patent: 7053188. Monoclonal antibodies specific for neoplasia-specific NADH: disulfide reductase
Morre, James D et al. United States Patent: 20030170757. Monoclonal antibodies specific for neoplasia-specific NADH: disulfide reductase
Mcintyre, John A. United States Patent: 20120107841. Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer's Disease

Vaccine Research (Cholesterol Removal From Human Serum)

Kamtchoua, Thierry, Monica Bologa, Robert Hopfer, David Neveu, Branda Hu, Xiaohua Sheng, Nicolas Corde, Catherine Pouzet, Gloria Zimmerman, and Sanjay Gurunathan. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.Vaccine (2012).

Posted on Date: 
Tue, 02/12/2013